Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Monday,Benzinga reports. The brokerage currently has a $30.00 target price on the stock.

Several other research firms also recently issued reports on VYGR. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Wedbush restated an “outperform” rating and issued a $9.00 target price (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. Cantor Fitzgerald began coverage on Voyager Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.72.

Voyager Therapeutics Trading Down 4.2 %

Shares of Voyager Therapeutics stock opened at $3.91 on Monday. The stock has a market cap of $213.59 million, a price-to-earnings ratio of 5.51 and a beta of 0.91. Voyager Therapeutics has a twelve month low of $3.88 and a twelve month high of $10.66. The company has a fifty day moving average price of $5.18 and a 200 day moving average price of $6.00.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 over the last ninety days. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP lifted its holdings in shares of Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after buying an additional 740,000 shares during the last quarter. Virtus Investment Advisers Inc. lifted its position in shares of Voyager Therapeutics by 59.0% in the 4th quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company’s stock worth $114,000 after acquiring an additional 7,457 shares during the period. Tema Etfs LLC acquired a new stake in shares of Voyager Therapeutics during the 4th quarter valued at about $85,000. Man Group plc bought a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $234,000. Finally, Farallon Capital Management LLC grew its position in Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after acquiring an additional 278,700 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.